Recombinant Human FCAR/CD89 Protein, CF
Recombinant Human FCAR/CD89 Protein, CF Summary
KD <10 nM.
Gln22-Asn227, with a C-terminal 6-His tag
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS.|
|Reconstitution||Reconstitute at 100 μg/mL in sterile PBS.|
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
FCAR, also called Fc alpha RI or CD89, is a variably glycosylated 50-100 kDa myeloid-specific type I transmembrane (TM) Fc receptor for IgA that is a member of the multichain immune recognition receptor (MIRR) family (1-3). Human FCAR contains a 21 amino acid (aa) signal sequence and extracellular (ECD), TM and cytoplasmic domains of 206, 19 and 41 aa, respectively (4). Arg230 within the TM domain supports interaction with the ITAM-containing signaling subunit, FcR gamma, which contains a TM Asp (5-7). Two ECD C2-type Ig-like domains (EC1 and 2) are oriented at right angles (8). Up to two molecules of FCAR can bind one molecule of serum IgA via EC1 (8). Many splice variants have been reported, but only two have been identified as proteins (9, 10). The a.2 form, which lacks 22 aa just prior to the TM domain, is exclusively expressed in alveolar macrophages. The a.3 form lacks EC2. FCAR binds monomeric, polymeric and secretory IgA, but does not mediate the barrier function of secretory IgA in mucosal epithelium (1-3). Shedding and circulation of polymeric IgA/FCAR immune complexes has been reported (11). Circulating neutrophils, eosinophils, and monocytes express FCAR (12). Tissue expression of FCAR is mainly from neutrophils; FCAR is downregulated as monocytes differentiate to tissue macrophages (12). On neutrophils, a significant amount of FCAR lacks FcR gamma, but can still be endocytosed to early endosomes and recycled to the cell surface (5). Binding of serum IgA to FCAR is transient and anti-inflammatory, inhibiting IgG or IgE-induced degranulation (6). Sustained aggregation of FCAR results in inflammatory responses (6). FcR gamma signaling is required for these and for transport to late endosomes (5-7). Human FCAR shows 55-58% aa identity with rat, horse and cow FCAR. No ortholog occurs in mouse. FCAR structure resembles the KIR/ILT/LIR/MIR family more than other IgA receptors, including pIgR, Fc alpha /μR, asialoglycoprotein receptor (ASGR1) and transferrin receptor (TfR) (1-3).
- Wines, B. D. and P. M. Hogarth (2006) Tissue Antigens 68:103.
- Otten, M. A. and M. van Egmon (2004) Immunol. Lett. 92:23.
- Montiero, R. C. and J. G. J. van de Winkel (2003) Annu. Rev. Immunol. 21:177.
- Maliszewski, C. R. et al. (1990) J. Exp. Med. 172:1665.
- Launay, P. et al. (1999) J. Biol. Chem. 274:7216.
- Pasquier, B. et al. (2005) Immunity 22:31.
- Shen, L. et al. (2001) Blood 97:205.
- Herr, Y. et al. (2003) Nature 423:614.
- Patry, C. et al. (1996) J. Immunol. 156:4442.
- Togo, S. et al. (2003) FEBS Lett. 535:205.
- van der Boog, P. J. M. et al. (2002) J. Immunol. 168:1252.
- Hamre, R. et al. (2003) Scand. J. Immunol. 57:506.
Citations for Recombinant Human FCAR/CD89 Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
Citations: Showing 1 - 2
Filter your results:
An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In Vivo.
Authors: Lohse S, Meyer S, Meulenbroek L, Jansen J, Nederend M, Kretschmer A, Klausz K, Moginger U, Derer S, Rosner T, Kellner C, Schewe D, Sondermann P, Tiwari S, Kolarich D, Peipp M, Leusen J, Valerius T
Cancer Res, 2016;76(2):403-17.
Sample Types: Protein
Applications: Surface Plasmon Resonance
Human IgA-binding peptides selected from random peptide libraries: affinity maturation and application in IgA purification.
Authors: Hatanaka T, Ohzono S, Park M, Sakamoto K, Tsukamoto S, Sugita R, Ishitobi H, Mori T, Ito O, Sorajo K, Sugimura K, Ham S, Ito Y
J Biol Chem, 2012;287(51):43126-36.
Sample Types: N/A
Applications: Surface Plasmon Resonance
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Protein Purification Kits
Reviews for Recombinant Human FCAR/CD89 Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human FCAR/CD89 Protein, CF and earn rewards!
Have you used Recombinant Human FCAR/CD89 Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image